After the July 2026 FDA decision, people with mild cognitive impairment due to early Alzheimer's can start Leqembi at home with weekly shots or in a clinic with IV infusions. Preparation for either route centers on confirming eligibility, completing gene and brain scans, and planning safety checks. Leqembi (lecanemab) is an antibody drug that targets amyloid-beta buildup in the brain.
Mild cognitive impairment means early memory and thinking changes that are noticeable but do not yet block daily tasks. According to the Eisai/Biogen approval notice on July 13, 2026, the Eisai/Biogen approval notice weekly at-home treatment can now begin from day one. Clinic infusions remain available, and patients can switch routes for flexibility.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the official guidance from NIH — Use this primary source to verify the official guidance.
- Apply through Multivu’s official page — Use this page to review requirements and apply directly.
Table of Contents
- What the at-home option changes
- Who can consider treatment?
- What safety steps come first?
- How do you prepare for shots versus infusions?
What the at-home option changes
The at-home start uses LEQEMBI IQLIK, a subcutaneous form given as 500 mg once weekly. That dose is two back-to-back 250 mg autoinjector shots of about 15 seconds each. After 18 months, the maintenance dose is 360 mg weekly. The IV form still starts at 10 mg/kg every two weeks over about one hour, then shifts after 18 months to 10 mg/kg every four weeks, according to FDA prescribing information via DailyMed. Patients may stay on one route or change between IV and shots.
The main practical shift is fewer infusion-center visits, not fewer medical checks. U.S. launch was planned for late August 2026, with availability reported August 24, 2026, according to Medscape reporting on home lecanemab. MRI follow-up, caregiver training, and clinician oversight still apply. Home treatment removes travel for dosing but keeps the same safety program.
Who can consider treatment?
Leqembi is only for adults with mild cognitive impairment or mild dementia due to Alzheimer's with confirmed amyloid-beta pathology. That match reflects the trial group. Confirmation requires amyloid testing ordered by the care team.
Use this check before booking a start date: Age alone does not qualify a person. Symptoms must fit early-stage disease and amyloid must be present. If either part is missing, treatment does not start.
- diagnosis of mild cognitive impairment or mild dementia linked to Alzheimer's
- positive amyloid-beta test result on record
- recent clinical visit to review other brain causes, drugs, and bleed risks
- caregiver or helper available to learn shots, watch for symptoms, and drive to scans
What safety steps come first?
Leqembi carries an FDA boxed warning for amyloid-related imaging abnormalities with swelling and bleeding that can be serious or fatal. Risk runs highest in people with two copies of ApoE e4, who make up about 15 percent of Alzheimer's patients. That risk shapes every preparation step. The FDA label calls for ApoE e4 testing before the first dose and a recent baseline brain MRI.
Follow-up MRIs occur within about one week before the 3rd, 5th, 7th, and 14th infusions. Report headache, confusion, dizziness, nausea, vision change, or trouble walking at once. Do not skip gene counseling or scan scheduling. Results may change the choice to start, delay dosing, or favor closer follow-up. Bring a full drug list, prior head scans, and emergency contacts to the consent visit.
How do you prepare for shots versus infusions?
For home shots, plan storage, technique, and backup care. Learn how to hold each autoinjector, time both shots, check the full dose went in, and record date and site. Keep clinic phone numbers posted and keep rides ready for MRI and urgent visits.
For IV care, plan vein access, infusion time, and travel. Each start-phase visit takes about one hour for the drip plus check-in and watch time. Ask who orders scans, who reviews results, and what cancels a dose. Both routes share the same next actions: Tell the team about blood thinners, planned surgery, missed doses, or new symptoms before each treatment day.
- complete ApoE testing and baseline MRI
- set MRI dates tied to early doses
- name one person to give shots or drive to infusions
- write down warning signs and the after-hours call path
You Might Also Like
- FDA’s 2026 At-Home Leqembi IQLIK Starting Dose: A Preparation Checklist for People With Mild Cognitive Impairment
- PrecivityAD2 Testing for Symptomatic Adults 40 and Older in 2026: Access, Cost, and Follow-Up Questions for People With Mild Cognitive Impairment
- UAS-CLEAR Dementia Care Research Data Priorities in 2026: Research Participation Questions for People With Mild Cognitive Impairment
